Daniel R. Chevallard
2019
In 2019, Daniel R. Chevallard earned a total compensation of $327.9K as Former Chief Financial Officer at Regulus Therapeutics, a 67% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $64,272 |
|---|---|
| Option Awards | $50,339 |
| Salary | $198,288 |
| Stock Awards | $5,863 |
| Other | $9,109 |
| Total | $327,871 |
Chevallard received $198.3K in salary, accounting for 60% of the total pay in 2019.
Chevallard also received $64.3K in non-equity incentive plan, $50.3K in option awards, $5.9K in stock awards and $9.1K in other compensation.
Rankings
In 2019, Daniel R. Chevallard's compensation ranked 12,766th out of 13,971 executives tracked by ExecPay. In other words, Chevallard earned more than 8.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 12,766 out of 13,971 | 9th |
Division Manufacturing | 5,169 out of 5,701 | 9th |
Major group Chemicals And Allied Products | 2,028 out of 2,200 | 8th |
Industry group Drugs | 1,746 out of 1,886 | 7th |
Industry Pharmaceutical Preparations | 1,293 out of 1,398 | 8th |
Source: SEC filing on April 29, 2020.
Chevallard's colleagues
We found three more compensation records of executives who worked with Daniel R. Chevallard at Regulus Therapeutics in 2019.